These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10371334)

  • 1. A simple index using video image analysis to predict disease outcome in primary breast cancer.
    Lockwood CA; Ricciardelli C; Raymond WA; Seshadri R; McCaul K; Horsfall DJ
    Int J Cancer; 1999 Jun; 84(3):203-8. PubMed ID: 10371334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple index to predict prognosis independent of axillary node information in breast cancer.
    Seshadri R; Horsfall DJ; McCaul K; Leong AS
    Aust N Z J Surg; 1997 Nov; 67(11):765-70. PubMed ID: 9396991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
    Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
    J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.
    Pich A; Margaria E; Chiusa L; Candelaresi G; Dal Canton O
    Br J Cancer; 1999 Feb; 79(5-6):959-64. PubMed ID: 10070897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis.
    Seshadri R; Leong AS; McCaul K; Firgaira FA; Setlur V; Horsfall DJ
    Int J Cancer; 1996 Apr; 69(2):135-41. PubMed ID: 8608982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort.
    Levesque MA; Yu H; Clark GM; Diamandis EP
    J Clin Oncol; 1998 Aug; 16(8):2641-50. PubMed ID: 9704714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Veronese SM; Maisano C; Scibilia J
    Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
    Meyer JS; Province MA
    Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers for predicting prostate cancer stage and survival.
    Dunsmuir WD; Gillett CE; Meyer LC; Young MP; Corbishley C; Eeles RA; Kirby RS
    BJU Int; 2000 Nov; 86(7):869-78. PubMed ID: 11069416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.
    Barbareschi M; Caffo O; Doglioni C; Fina P; Marchetti A; Buttitta F; Leek R; Morelli L; Leonardi E; Bevilacqua G; Dalla Palma P; Harris AL
    Br J Cancer; 1996 Jul; 74(2):208-15. PubMed ID: 8688323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.